SmartTarget

by Focalyx  · Based in United States → — Minimally Invasive Cancer Eradication
Interventional Radiology Radiology Urology

Contact for pricing
Regulatory Status Disclosed

Overview

SmartTarget is an AI-powered image fusion software developed by SmartTarget Ltd, a spin-out company of University College London (UCL). It is designed to enhance the accuracy of prostate cancer diagnosis and treatment by guiding targeted biopsies and minimally-invasive therapies. The software fuses diagnostic information from magnetic resonance imaging (MRI) with real-time transrectal ultrasound (TRUS) images, creating a 3D model of the prostate and identifying malignancies. This allows clinicians to precisely target areas of concern during procedures. The system features a clinician-designed, intuitive user interface and is agnostic to specific MR and ultrasound equipment. Its core technology utilizes machine learning techniques to assure accurate deformation and compensate for changes in prostate shape and position between images. The technology and related assets of SmartTarget were acquired by Miami-based Intuitive Fusion LLC in January 2020 for inclusion in its Focalyx Fusion product.

Note:The provided prompt indicated this tool is for a ‘physician directory’. This JSON reflects the actual product’s functionality.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • MRI-Ultrasound image fusion for prostate targeting
  • 3D reconstruction of transrectal ultrasound (TRUS) images
  • Real-time surgical guidance during biopsy and treatment
  • Precision targeting for prostate biopsy procedures
  • Supports minimally-invasive prostate cancer treatments (e.g., focal therapy)
  • Clinician-designed, intuitive user interface
  • Agnostic to specific MR and ultrasound equipment
  • Machine learning for accurate deformation of MR models
  • 2D and 3D image visualization features (review, multi-planar views, annotation)
  • Automated compensation for changes in prostate shape and position

Use Cases

  • Targeted prostate biopsy for cancer detection
  • Image-guided interventional procedures involving the prostate gland
  • Minimally-invasive prostate cancer treatments (focal therapy)
  • Enhanced visualization during prostate diagnostic and treatment procedures
  • Computer-assisted surgical planning for prostate cancer
  • Improving detection rates of clinically significant prostate cancer

What Physicians Need to Know

Key Capabilities
SmartTarget, integrated into Focalyx Fusion, offers advanced MRI-ultrasound image fusion for prostate cancer. It features bespoke algorithms for realistic deformation of the MR model, mathematically best-fit image fusion, live needle guidance, and 3D visualization for precise targeting. It supports computer-assisted surgical planning and real-time surgical guidance by supplementing real-time ultrasound imaging. The system is designed to precisely locate and treat cancerous lesions while sparing healthy tissue.
Clinical Utility
Focalyx Fusion enables tissue-sparing focal therapy for prostate cancer, aiming to preserve quality of life with durable oncologic control, continence, and potency. It streamlines prostate cancer care with precise imaging and targeted treatment, allowing for in-office or outpatient procedures with minimal downtime. The technology is used for diagnosis (Focalyx Dx), biopsy (Focalyx Bx), and treatment (Focalyx Tx), providing a "GPS-like" solution for the prostate gland.
Integration Options
Focalyx Fusion is designed to integrate seamlessly into existing urology practices and workflows. It is compatible with various ultrasound machines and positioning systems, and its design is agnostic to the treatment modality, working with cryoablation, HIFU, IRE, and more.
Compliance Status
Focalyx Fusion is an FDA-cleared Software as a Medical Device (SaMD). There was a Class 2 Device Recall (Z-1243-2026) for Focalyx Fusion (software versions 1.3, 1.5) due to potential issues with Windows 10 compatibility, which could cause patient harm or treatment delays. The firm recommended stopping use until verified/validated with Windows 11.
User Experience
The system features a clinician-designed user interface and intuitive workflow, making it fast and easy for ultrasound and radiologist-friendly MR contouring. It is described as having an easy-to-use interface specific to urologists. The Focalyx App facilitates patient-physician interaction, health monitoring, personal health records, and provides educational resources.
Support Quality
Focalyx offers hands-on training, case observations, and an easily accessible course.
Implementation Complexity
The Focalyx system is designed for easy integration into any clinical setting, fitting seamlessly into existing urology practices.
Evidence Base
Focalyx is backed by 20 years of research and clinical evidence. Studies show approximately 86% of patients are cancer-free at 5 years in focal therapy cohorts. Clinical data indicates preservation of urinary and sexual function, with around 94-95% reporting same or better urinary function and 88% maintaining erections post-ablation. The technology was developed by clinicians at University College London Hospitals and researchers in UCL's Centre for Medical Image Computing. Over 300 men have been accrued in a clinical trial (NCT02381990) evaluating the feasibility of Focalyx solutions. Publications and in-depth case studies detail the impact of their work.
Physician Tip

Focalyx Fusion offers a precise, minimally invasive approach to prostate cancer management, allowing for targeted diagnosis, biopsy, and treatment while aiming to preserve patient quality of life. Consider its utility for appropriately selected low-risk and favorable-intermediate prostate cancer patients. The system's deformable fusion model and real-time guidance can enhance targeting accuracy. Be aware of the Windows 10 compatibility recall and ensure the system is validated for your operating environment. The integrated patient app can facilitate follow-up and communication.

Focalyx Fusion is designed for seamless integration into existing urology practice workflows and is compatible with various ultrasound manufacturers and positioning systems. It is also energy-agnostic, supporting different ablative modalities like cryoablation, HIFU, and IRE.

Details

Category Oncology AI, Radiology & Imaging AI, Surgical AI
Pricing Contact for pricing
DeploymentOn-premise (PC-based software)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Interventional Radiology, Radiology, Urology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2017-06-07K170250 510(k)SmartTarget

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate SmartTarget

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for SmartTarget.

Loading videos...

View all on YouTube

Frequently Asked Questions

SmartTarget technology, now part of Focalyx Fusion, aids physicians in precise prostate cancer care by integrating MRI and ultrasound imaging. It creates an accurate 3D model of the prostate to guide targeted biopsies and treatments, allowing for the ablation of cancerous lesions while preserving healthy tissue. This approach aims to minimize damage and side effects, leading to quicker recovery and improved quality of life for patients.
The use of AI in oncology, including tools like SmartTarget, requires continuous compliance with regulatory frameworks to address ethical risks. Regulatory bodies are establishing guidelines for AI in healthcare, with a focus on evidence-based and predictive decision support. Ensuring data security, transparency in AI model programming, and addressing potential biases are critical for responsible AI implementation in clinical practice.
While AI in oncology offers significant potential, limitations exist. These include the need for large datasets for training and validation, potential for AI to generate incorrect or misleading information (hallucinations), and challenges in integrating AI systems into existing clinical workflows. There are also concerns about the interpretability of AI decisions, potential for increased healthcare costs due to AI recommending more tests, and the environmental impact of running AI systems.
Yes, the broader field of AI in oncology is rapidly expanding with various tools for diagnosis, treatment planning, and patient monitoring. While SmartTarget focuses on MRI-ultrasound fusion for prostate cancer, other AI tools like IBM Watson for Oncology and Tempus offer advanced decision support, genomic sequencing integration, and clinical trial matching for various cancer types. Other AI-powered platforms are also emerging for image interpretation, risk prediction, and treatment outcome forecasting.
Specific pricing for SmartTarget (Focalyx Fusion) is not publicly available, as is common with many clinical AI tools. Generally, pricing models for clinical AI vary widely, from free tiers to enterprise contracts. Some tools offer self-serve subscriptions for individual clinicians, while others require sales-led enterprise agreements, making direct price comparisons challenging.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-14 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.